Cantor Fitzgerald Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and raises the price target from $115 to $116.
August 02, 2024 | 3:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has maintained its Overweight rating on Ultragenyx Pharmaceutical and slightly raised the price target from $115 to $116.
The maintenance of an Overweight rating and a slight increase in the price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100